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pABSTRACT
Background: Low rates of treatmentmodification in
patients with insufficiently controlled risk factors are
common in type 2 diabetes. Although adherence prob-
lems are often mentioned in surveys as a reason for not
intensifying treatment, observational studies have
shown inconclusive results.
Objective: To assess how medication adherence af-
fects treatment modifications for hypertension and hy-
perglycemia in patients with type 2 diabetes.
Methods: This was a cohort study of 11,268 pri-
mary care patients with type 2 diabetes in the Nether-
lands. Inclusion criteria were diagnosis before 2007,
1 prescription to antihypertensive or glucose-regulat-
ing medication in the preceding 6 months, and a sys-
tolic blood pressure level140mmHg or glycosylated
hemoglobin 7% in 2007. Patients on maximal treat-
ment were excluded. Treatment modifications as ob-
served from prescriptions were classified as none, dose
increase, dose decrease, class switch, class addition, or
class discontinuation. Refill adherence was assessed as
medication possession ratio or length of last gap be-
tween refills. We performed multilevel multinomial re-
gression analysis to test for associations.
Results: We included 4980 diabetic patients with
elevated blood pressure and 2945 diabetic patients
with elevated glycosylated hemoglobin levels. Patients
with lower adherence for antihypertensive drugs were
more likely to have those medications discontinued
(odds ratio [OR] for every 10% lower medication pos-
session ratio 1.22; 95% CI, 1.11–1.33) or the dose
decreased (OR  1.14; CI 1.01–1.28). For glucose-
January 2011regulating medication, dose increases (OR  0.92;
95% CI, 0.85–0.98) and medication additions (OR 
0.90; 95% CI, 0.82–0.99) were less likely in patients
with lower adherence levels.
Conclusions: Low adherence inhibits the intensifi-
cation of glucose-regulating but not antihypertensive
medication in type 2 diabetic patients with insuffi-
ciently controlled risk factors in the Netherlands. Ad-
herence problems may lead to diminished or even dis-
continued antihypertensive treatment. (Clin Ther.
2011;33:121–134) © 2011 Elsevier HS Journals, Inc.
Key words: hyperglycemia, hypertension, medica-
tion adherence, primary care, therapy modification,
type 2 diabetes.
INTRODUCTION
Despite considerable progress in the field of hyperten-
sion and other cardiovascular risk factor management
during the last decade, undertreatment remains a topic
of importance, especially in high-risk populations such
as patients with type 2 diabetes.1–4 Both poor adher-
nce and lack of treatment intensification seem com-
on in diabetic patients not reaching target risk factor
evels.5 Several studies have looked into reasons for
hysicians not acting when confronted with patients
*Members of GIANNT are listed in the Acknowledgments.
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Clinical Therapeuticswith elevated risk factor levels.6–12 Physicians may be
reluctant to intensify pharmacotherapy when patients
already take multiple medications,6 when patients
ave difficulty with lifestyle modifications,7 or when
patients are reluctant to take medication.8 Perception
of poor adherence has often been mentioned in surveys
by physicians as a reason not to intensify treat-
ment.5,10,11 Observational studies, however, have re-
ported conflicting results on the association between
medication adherence and treatment intensifica-
tion.13–17 Both negative and positive associations have
een observed between suboptimal adherence and
reatment modifications,13,14,17 whereas no such asso-
ciations were found in other studies.15,16
Some disagreements in these observational studies
may be due to the differences in definitions of both
medication adherence and treatment intensification.
Medication adherence has been assessed using various
measures based on prescription refill data.18–20 This
often leads to a binary classification between patients
collecting sufficient amounts of pills or prescription
refills and those collecting inadequate numbers of pills
or having large gaps between refills. Treatment inten-
sification is also commonly assessed as a binary out-
come (intensification or not), including sometimes only
dose increase or addition of a new drug as intensifica-
tion13–15 and sometimes switches within or between
classes of drugs.16,17 All other therapy modifications
re classified as no intensification, leading to inconsis-
ent definitions of what is considered to be no treat-
ent intensification.
Aside from these inconsistencies, binary definitions
f therapy modifications can obscure meaningful asso-
iations. In patients with adherence problems, it is usu-
lly appropriate not to intensify therapy; therefore,
esting is performed to determine whether low adher-
nce levels are associated with no intensification. Spe-
ific therapy modifications, however, may be appro-
riate, depending on the underlying reasons for
onadherence. For instance, when patients are non-
dherent because of perceived side effects, switching
o another drug class or decreasing the medication
ose may be warranted instead of not intensifying
reatment. To our knowledge there are no studies on
he association between medication adherence and
istinct therapy modifications, separating intensifi-
ations from switches, dose changes, discontinua-
ion, or no change in medication.
122The aim of this study was to assess how patients’
edication adherence affects distinct prescribing
odifications for hypertension and hyperglycemia in
ype 2 diabetic patients in the Netherlands. For this,
e include different continuous and binary adher-
nce estimates.
PATIENTS AND METHODS
We conducted a cohort study to assess the influence
of medication adherence on prescribing modifica-
tions for hypertension and hyperglycemia in patients
with type 2 diabetes in the Netherlands. Clinical
measurements, prescriptions, and demographic data
for patients with type 2 diabetes were collected from
the Groningen Initiative to Analyze Type 2 Diabetes
Treatment (GIANTT) database. We used data from
2007, which was the most recent year with complete
follow-up available. This Dutch database contains
anonymized longitudinal information retrieved from
electronic medical records of general practitioners
(GPs).21 In the Netherlands, patients are registered
ith a single GP. The GPs in our study prescribe
lectronically, ensuring full information on pre-
cribed drugs and dosing schemes. Having electronic
edical records allows the GPs to view recent pre-
cribing history, a minimal prerequisite for detecting
ossible adherence issues. Ethics committee ap-
roval was not required because research using
nonymous medical records in the Netherlands does
ot warrant it.22
Study Population
The study population consisted of patients with a
diagnosis of type 2 diabetes who were managed by 142
GPs. Patients were included if they were diagnosed be-
fore the year 2007, had 1 risk factor measurement
above the treatment target (140 mm Hg for systolic
blood pressure; 7% for glycosylated hemoglobin
[HbA1c]) in 2007, and received 1prescription for an
antihypertensive or glucose-regulating drug in the pre-
ceding 6 months. Because our data do not allow for
assessing referrals to specialist care nor changes in in-
sulin dose, we excluded patients from the analyses if
they had already received3 drug classes on maximal
maintenance dose for blood pressure lowering or if
they had been prescribed insulin as glucose-regulating
medication (see Table 1 for definitions).
Volume 33 Number 1
J. Voorham et al.Treatment Modifications
For each patient, the first elevated risk factor obser-
vation in 2007was taken as the index observation. The
primary outcome in our study was the first therapy
modification after the index observation. Therapy
modifications were assessed during a 60-day period
starting on the index date. Modifications as observed
from prescriptions were classified as follows: none,
dose increase, dose decrease, class switch, addition of a
new class, and discontinuation of a class (see Table 1
for definitions). For glucose-regulating medication, we
included start of insulin as a distinct treatment modi-
fication. In the case of multiple therapy intensifica-
tions, we classified insulin start as predominant over
other intensifications and class addition as predomi-
nant over dose increase. In the case of multiple reduc-
tions, we classified class discontinuation as predomi-
Table I. Medication definitions used.
Antihypertensive drug classes Renin-angioten
calcium channe
Glucose-regulating drug classes Metformin; sulf
(repaglinide, ex
Maximal treatment For glucose-reg
having reached
medication, 3 o
dose was define
Dose increase Increase of the
Dose decrease Decrease of the
Start Prescription of
period
Discontinuation Prescription of
date of the last
we used the da
another drug o
of the last presc
calculated end
before the inde
discontinuation
Switch A class was disc
days of the disc
Addition A new class sta
days of the star
* 270 days corresponds with 3 times the maximal durationnant over dose decrease.
January 2011Patients with opposing modifications (n  17)
were excluded (eg, a dose increase coinciding with a
dose decrease). Patients who left the practice within
270 days from the index observation were excluded,
owing to insufficient follow-up. For comparison, we
also constructed the commonly used binary out-
come: 1) intensification (ie, dose increase or addition
of class), or 2) no intensification (all other cases).
Medication Adherence
Medication adherence was assessed at the drug class
level using prescription refill data in the 1-year period
before the index date. Drug classes signify groups or
single drugs that can be expected being prescribed con-
currently (Table 1). Within a drug class, on the other
hand, drugs are expected to be prescribed sequentially.
The algorithm used to calculate the adherence param-
dosterone system inhibitors; diuretics; - blockers;
kers; centrally acting antihypertensives
reas; acarbose; thiazolidinediones; other oral drugs
e)
g medication, prescription of insulin was defined as
mal medication; for blood pressure-lowering
re drug classes prescribed at maximum maintenance
maximal treatment
ribed daily dose of a drug
ribed daily dose of a drug
ss not previously prescribed within a 270-day*
s not prescribed within a 270-day* period since the
ription. To estimate the date of the discontinuation
coinciding event: a dose increase or decrease of
ition of a new class that occurred during the course
n. In cases of no coinciding event, we used the
f the last prescription. A discontinuation occurring
counted as a class discontinuation if the derived
was within 7 days of the index date
ued (see above) and a new class started within 7
uation date
ithout another class being discontinued within 7
rescription for chronic drug use in the Netherlands.sin-al
l bloc
onylu
enatid
ulatin
maxi
r mo
d as
presc
presc
a cla
a clas
presc
te of a
r add
riptio
date o
x date
date
ontin
ontin
rted w
t date
of a peters corrects for overlapping prescriptions, dose
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Clinical Therapeuticschanges, and drug and class switches. Details on this
algorithm are available in Appendix I.
We calculated 2 common adherence measures: the
first expresses the length of the most recent gap be-
tween 2 prescriptions (period without medication);
the second calculates the overall medication posses-
sion ratio (MPR) up to the index date.19,23 The MPR
assesses the number of days a drug is prescribed in
relation to the prescribing period and is a measure of
overall medication availability. The length of the
most recent gap may be more visible to prescribing
physicians than a period assessment like the MPR.
The MPR, however, may better reflect chronic sub-
optimal adherence. We quantified adherence using
the largest last gap in any of the concurrently pre-
scribed drug classes within either antihypertensive
or glucose-regulating medication and, analogously,
used the lowest MPR within each therapeutic group.
Statistical Analysis
To analyze the association between adherence
and treatment modification, we calculated adjusted
odds ratios (OR) and their 95% CI using multilevel
multinomial logistic regression with Stata version 11
(StataCorp LP, College Station, Texas), correcting
for clustering at the GP level. Associations were con-
sidered significant when the 95%CI did not include the
value of 1.0. Potential confounders added to the mod-
els were the level of the index observation for HbA1c
and systolic blood pressure, age, sex, diabetes duration
(as provided by the GP), number of risk factor–specific
drug classes used, and number of other chronic drugs
used. In prescribing glucose-regulating medication it is
recommended to increase a drug’s dose until its maxi-
mal dose is reached24; therefore, we included a binary
ariable to indicate whether all drugs used were de-
cribed at maximal maintenance dose or not.
To assess the effect of using different adherence and
utcome measures, all analyses were conducted using ei-
her the last gap or the MPR as continuous adherence
easures and using distinct treatment modifications as
ell as the binary intensification outcome.
AnORwas presented for every 10%decrease inMPR
r every 14-day increase of last gap length, both repre-
enting lower adherence levels. In additional analyses, we
sed categorical instead of continuous adherence mea-
ures based on commonly used end points of 15 and 30
ays for gap length and of 70% and 80% forMPR level. c
124RESULTS
Of the 11,268 primary care patients with type 2 diabe-
tes, 4980 and 2945 were included in the analyses for
antihypertensive and glucose-regulating medication,
respectively (Figure 1). The patient populations dif-
fered slightly with respect to percentage female, age,
and diabetes duration (Table 2).
The most frequently used antihypertensive drug
classes were renin-angiotensin-aldosterone system in-
hibitors, diuretics, and -blockers. One third of pa-
ients were on monotherapy, whereas 38% used 2
Figure 1. Patient selection for antihypertensive (A)
and glucose-regulating (B) medication.
SBP  systolic blood pressure; DM 
diabetes mellitus; HbA1c  glycosylated
hemoglobin.lasses (Table 2). Most patients showed high adher-
Volume 33 Number 1
J. Voorham et al.Table II. Characteristics of patient population and medication use (numbers [%] presented, unless otherwise
specified).
Antihypertensive Glucose Regulating
No. of patients 4980 2945
Female 2812 (56.5) 1483 (50.4)
Systolic blood pressure, mean (SD) 154.6 (14.9)
HbA1c, %, mean (SD) 7.6 (0.8)
Age, y, mean (SD) 66.7 (11.1) 66.1 (12.1)
Diabetes duration, y, mean (SD) 6.0 (5.7) 5.7 (5.2)
No. of other chronic drugs, median (IQR) 4 (3) 4 (4)
Drug classes used prior to index date
RAAS inhibitors 3547 (71%)
Diuretics 2669 (54%)
ß-blocking agents 2306 (46%)
Calcium channel blockers 1054 (21%)
Other antihypertensives 87 (2%)
Biguanides (ie, metformin) 2324 (79%)
Sulfonylureas 2021 (69%)
-Glucosidase inhibitors (ie, acarbose) 12 (0.4%)
Thiazolidinediones 381 (13%)
Other oral diabetes drugs 2 (0.1%)
Number of drug classes used
1 class 1675 (33.6%) 1339 (45.5%)
2 classes 1913 (38.4%) 1417 (48.1%)
3 classes 1392 (28.0%) 189 (6.4%)
All drugs at maximal dose 7 (0.1%) 219 (7.4%)
MPR classes
50% 292 (5.9%) 107 (3.6%)
50 to 70% 304 (6.1%) 219 (7.4%)
70 to 80% 314 (6.3%) 249 (8.5%)
80% 4070 (81.7%) 2370 (80.5%)
Last gap length classes
15 days 3761 (75.5%) 2424 (82.3%)
15 to 30 days 519 (10.4%) 239 (8.1%)
30 days 700 (14.1%) 282 (9.6%)
Number of drug classes with lowest MPR
1 class 3844 (77.2%) 2523 (85.7%)
2 classes 867 (17.4%) 391 (13.3%)
3 classes 269 (5.4%) 31 (1.1%)
Number of drug classes with largest last gap
1 class 3673 (73.8%) 2130 (72.3%)
2 classes 986 (19.8%) 742 (25.2%)
3 classes 321 (6.4%) 73 (2.5%)
HbA1c glycosylated hemoglobin; IQR interquartile range;MPRmedication possession ratio; RAAS renin-angiotensin-
aldosterone.January 2011 125
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Clinical Therapeuticsence to antihypertensive medication (80% MPR
[82% of patients] or last gap length15 days [76%]);
low adherence was found in 6% (MPR50%) to 14%
(last gap length 30 days).
The most frequently used glucose-regulating drugs
were metformin and sulfonylureas. Monotherapy was
observed in 46% of patients, whereas 48% used 2
medication classes. In 81% of the patients, adherence
was 80% MPR, whereas 83% had a last gap length
15 days. Only 4% had anMPR below 50%, whereas
10% had a last gap length of 30 days.
In patients using multiple drugs for the same indica-
ion, suboptimal adherence was mostly limited to a
ingle drug class. Of patients with adherence levels of
PR 80% or last gap 15 days using 2 drugs,
etween 89% and 96% of the adherence problem oc-
urred in a single drug class.
In 86% of patients using antihypertensive medica-
ion and 69% of those using glucose-regulating medi-
ation, no therapy modification was observed within
he 60-day period following the elevated risk factor
evel (Table 3). The most frequently observed modifi-
ations for antihypertensive and glucose-regulating
edications were dose increase (2.9% and 17.2%, re-
pectively) and addition of a new drug class (7.4% and
.0%, respectively). The least frequent modification
as a class switch. Half of the treatment modifications
ccurred within 14 and 17 days for antihypertensive
Table III. First therapy modifications within 60 days
Antihyperten
Modification n
None 4301
Increase 144
Decrease 65
Switch 14
Addition* 370
Discontinuation 86
Insulin start —
Total 4980
* Additions by switching to a combination drug occurred i
glucose-regulating medication.nd glucose-regulating medication, respectively.
126Antihypertensive Medication Treatment
Modification
Patients with lower adherence, expressed as lower
levels of MPR or higher levels of last gap, were more
likely to have an antihypertensive drug class discon-
tinued (Figure 2) (OR  1.22, 95% CI, 1.11–1.33
or MPR [–10%]; OR  1.11, 95% CI, 1.05–1.17
for last gap [14 days]). The likelihood of a dose
increase was not significantly lower in patients with
lower adherence levels (CI intervals including 1.0).
Only for the MPR measure were patients with lower
adherence levels more likely to receive a dose de-
crease (OR1.14, 95% CI, 1.01–1.28). When using
the binary outcome of treatment intensification, we
did not find significant associations with the adher-
ence measures (OR  1.04, 95% CI, 0.99–1.10 for
PR [–10%]; OR  1.00, 95% CI, 0.97–1.04 for
ast gap [14 days]).
Glucose-Regulating Medication Treatment
Modification
For glucose-regulating medication, we observed a
lower likelihood for dose increases in patients with
lower adherence levels using either adherence measure
(Figure 2) (OR  0.92, 95% CI, 0.85–0.98 for MPR
[–10%]; OR  0.88, 95% CI, 0.81–0.96 for last gap
[14 days]). Only for the MPR measure did we find a
lower likelihood for an addition of a new class in pa-
tients with lower adherence levels (Figure 2) (OR 
the elevated risk factor observation (index date).
Glucose Regulating
% n %
86.4 2030 68.9
2.9 506 17.2
1.3 71 2.4
0.3 12 0.4
7.4 234 8.0
1.7 66 2.2
— 26 0.9
2945
ases with antihypertensive medication and in 4 cases withafter
sive
n 17 c0.90, 95% CI, 0.82–0.99). The level of adherence did
Volume 33 Number 1
J. Voorham et al.not significantly affect starting with insulin. The binary
outcome of intensification also showed that a lower
Intensific
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MPR
Last Gap
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Antihypertensive
Adjusted OR
0.7 0.8 0.9 1 1.1 1.2 1.3 1.4
Adjusted OR
0.7 0.8 0.9 1 1.1 1.2 1.3 1.4
Adjusted OR
0.7 0.8 0.9 1 1.1 1.2 1.3 1.4
Adjusted OR
0.7 0.8 0.9 1 1.1 1.2 1.3 1.4
Intensific
In
De
S
Ad
Insu
Discon
Figure 2. The influence of medication adherence ex
decrease) and (B) length of last gap (14 d
therapy modifications for antihypertensive
(right). Presented are odds ratios (OR) a
number of risk factor–specific drug classes
dosing for glucose-regulating medication. Elevel of adherence was associated with a lower proba-
January 2011bility to intensify treatment (OR  0.92, 95% CI,
0.87–0.98 for MPR [–10%]; OR  0.93, 95% CI,
binary
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Clinical TherapeuticsCategorical Adherence Measures
For several associations significance was lost when
using categorical adherence measures. For antihyper-
tensive medication, only the association between the
MPR measures and dose decrease (OR  2.23, 95%
I, 1.23–4.03 for MPR [70%]) or drug class discon-
inuation (OR  2.37, 95% CI, 1.42–3.94 for MPR
70%]) remained significant, whereas those for the
ategorical last gap measures did not (Appendix II, CI
ncluding 1.0). For glucose-regulating drugs, the asso-
iations with class addition and dose increase were lost
n the cases of categorical MPR and last gap (30
ays) measure (Appendix II, CI including 1.0).
DISCUSSION
In patients with a low adherence to antihypertensive
drugs, we observed a higher likelihood to discontinue
the antihypertensive drug treatment. This result was in
contrast to glucose-regulating medication in which a
lower adherence was associated with fewer dose in-
creases and fewer additions of a new drug class, indi-
cating the expected reaction of not intensifying treat-
ment in case of observed low adherence.
The negative association between suboptimal ad-
herence and treatment intensification may thus depend
more on the therapeutic area than on the definitions of
adherence or treatment intensification. The effect seen
for glucose-regulating medication was consistent for
the different definitions. Physicians appear to take ad-
herence into account when confronted with insuffi-
cient glycemic control by not intensifying the glucose-
regulating treatment in patients with low adherence
levels.13 For antihypertensive treatment; however, we
ound no such association. This result is consistent
ith findings of other studies focussing on antihyper-
ensive treatment.14,16 This dissimilar finding between
he 2 therapeutic areas can be caused by differences in
ttention given to adherence but also by reasons under-
ying adherence and related possible reactions to non-
dherence at physician and patient level.
In previous studies, we have found indications for
glucose-centered approach to diabetes risk factor
anagement,1,25 which also has been reported by
ther investigators.26,27 Such a management strategy
ay lead to more attention and, thereby, higher
wareness of adherence problems for glucose-regu-
ating medication. In addition, the link between sub-
ptimal adherence and risk factor levels may be less
lear for blood pressure than for HbA1c.
13 This can s
128urther diminish the physicians’ awareness of the un-
erlying cause of suboptimal blood pressure control.
owever, even when the physician is aware of a
otential adherence problem, differences in patients’
eactions also can explain the differences in observed
reatment modifications. Self-reported adherence of
atients was found to be higher with antihyperten-
ive than glucose-regulating medication,28 whereas
refill rates have shown the opposite results.29,30
These findings imply that patients either overesti-
mate adherence or are more reluctant to admit ad-
herence problems with antihypertensive medication
than glucose-regulating medication. All these factors
contribute to the pattern we observed, where physi-
cians intensify antihypertensive treatment regardless
of low medication adherence levels.
We did observe other treatment modifications in pa-
tients with low adherence to antihypertensive medica-
tion. Such patients had a higher probability to discon-
tinue a drug class. This finding of poor adherence to
antihypertensive drugs being a strong predictor of dis-
continuation has been observed before,31 which may
indicate a patient-driven pattern of nonadherence
rather than a decision of the physician to modify the
treatment. Patients with low adherence to antihyper-
tensive drugs, however, tended to receive more dose
decreases and more additions of a new drug class,
which are treatment modifications made by physicians.
A pharmacy database study in the Netherlands, which
focused on first-time users of antihypertensive drugs,
found a similar association.17 This finding may be ex-
lained by reactions to perceived adverse effects under-
ying suboptimal adherence. Especially for antihyper-
ensive treatment, there are usually many options to
ecrease the dose of one drug while adding another
rug in order to increase effectiveness and reduce ad-
erse effects.
The real barrier to better risk factor control may
ot be addressed if treatment is intensified despite
ow adherence.14,32 Physicians may have trouble de-
tecting nonadherence in daily practice. There is a
need for better detection and visibility of adher-
ence,16,33 because correctly distinguishing nonre-
ponse to therapy from nonadherence is important.
urrently, the GP systems do not provide active
eedback regarding possible adherence problems.
uch tools, however, could be implemented easily in
he medical record systems when physicians pre-
cribe electronically. In our study, the choice of the
Volume 33 Number 1
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tent. The MPR, which is an overall period adherence
estimate, was more strongly related with treatment
modifications than an adherence measure based on
the last gap between prescription refills. It is possi-
ble, therefore, that the MPR better reflects adherence
judgments made by physicians.
When looking at treatment modification as a binary
outcome, some interesting findings are lost. Although
the conclusions are similar regarding the associations
between adherence and distinct intensifications for glu-
cose-regulating medication (ie, less intensification in
patients with lower adherence levels), they are different
for antihypertensive medication. Using a binary out-
come, one may conclude that there is no association
between adherence and treatment changes, whereas
our study showed that adherence levels are associated
with specific treatment modifications, such as discon-
tinuation, dose decrease, and addition of a new drug
class. Such modifications could be considered appro-
priate action in patients not adherent to treatment
when they have experienced adverse effects. Also, by
classifying various modifications in the binary out-
come as “no intensification,” one could erroneously
observe a negative association between adherence and
intensification.
Types and number of drugs used in our study
population are comparable to those reported else-
where.16,34–36 Using the common cutoff point for
adherence (80% MPR), the level of adherence ob-
served in our study population is comparable to
some other studies’ findings,5,30 although much
ower levels also have been reported.16,18 These dif-
ferences could be caused by differences in the health
care system and reimbursement, patient population,
and data source used. We used electronic prescribing
data, whereas others have used dispensing data or
claims databases.5,16,30 Although these sources are
all related, lower adherence levels may be observed
using dispensing data.33 When we compare the re-
ults obtained from the categorical adherence mea-
ures to the results from the continuous ones, we see
hat we lose considerable power to detect associa-
ions, which can be attributable to a lower precision
f estimates and to the (arbitrary) choice of the cut-
ff points. Therefore, as has been recommended be-
ore,18 it is better to use continuous measures in
tudies of adherence.
January 2011Strengths and Limitations
We used longitudinal information retrieved from
electronic medical records of GPs. This approach has
both advantages and disadvantages. The detailed lon-
gitudinal dataset enabled us to consider the first treat-
ment modification within 60 days after an elevated risk
factor observation, which is in contrast to other studies
that looked at treatment intensifications occurring in
longer periods irrespective of whether other modifica-
tions preceded these.5,13,15,17 Using a short period
makes it more likely that the treatment modification is
indeed a reaction to the observed elevated risk factor
level. The obvious limitation is that we were unable to
assess which other actions may have been taken to
improve medication adherence or who took the initia-
tive to discontinue the medication. It is possible that in
some cases the GPs decided to improve adherence by
educating and motivating the patient as well as in-
crease treatment at the same time. This type of action,
however, has the risk of predisposing patients to
overtreatment.
Patient and disease complexity could confound
the associations between adherence and treatment
intensification. Although we corrected for proxies of
this (diabetes duration, age, and polypharmacy) in
our analyses, residual confounding cannot be
excluded.
Using prescription refill data for calculating adher-
ence has the disadvantage of overestimating actual ad-
herence, because patients may collect their prescrip-
tions and not actually take the medication. On the
other hand, although these data do not reflect “true”
medication adherence, they reflect prescription refill
adherence as can be observed by the GPs from their
records. In addition, using prescription data from elec-
tronic medical records has the advantage of having a
direct measure of the treatment modifications made by
the GPs. Our data did not allow for correcting medi-
cation use for periods of inpatient hospitalization. Al-
though such periods do not necessarily result in gaps in
home medication use, because patients sometimes use
their home medication in the hospital, this limitation
may have resulted in underestimation of patients’ ad-
herence levels.
Finally, there is no best method for measuring ad-
herence using prescription data,19,23 which is why we
chose to use 2 different adherence measures. There is
also no consensus on how to calculate adherence in
patients usingmultiple drugs for the same indication.37
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Clinical TherapeuticsWe focused on the drug with the poorest adherence,
because we expect this to be relevant information for
the prescriber, and patients using multiple drugs can
show poor adherence on a single drug.29 Our results
confirm that in patients on multitherapy poor adher-
ence occurs predominantly in a single drug class. By
averaging adherence measures over concurrently used
drugs, the power to assess an association with nonad-
herence to a single drug is decreased.
CONCLUSIONS
This study demonstrates that low adherence to glu-
cose-regulating drugs does reduce the chance of inten-
sifying such treatment in insufficiently controlled pa-
tients with type 2 diabetes in the Netherlands. This did
not occur for antihypertensive treatment, indicating
that adherence problems cannot explain the lack of
antihypertensive treatment intensification in these pa-
tients. Low adherence may lead to other treatment
modifications, which are overlooked when focusing
only on whether the treatment is intensified. Our data
suggest that this is the case for antihypertensive medi-
cation, where low adherence may lead to diminishing
or the discontinuation of such treatment in patients
with type 2 diabetes.
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Clinical TherapeuticsAppendix I. Prescriptions (Rx) preprocessing.
Period definition All Rx of the therapeutic class prescribed in study
period  270 days
Correct erroneous Rx Exclude Rx with calculated duration 2 days
Correct concomitant use of same drug Sum daily use within first Rx and set to longest
duration and delete the second
Correct stockpiled Rx Exclude second Rx if gap following Rx is 80% of the
summed calculated duration
Correct isolated short Rx Exclude Rx with calculated duration 15 days and
not repeated within 7 days
Correct for daily use change Change in daily use within a single ATC results in
correction of Rx duration
Correct switch to/from combination Correct Rx duration
Correct variations in Rx collection at ATC level Line up at ATC level
Correct switch to other drug Correct Rx duration in case of switch to another ATC
Correct variations in Rx Line up
Correct class switch Adjust period end in case of a switch to another
therapeutic class
Correct class start Adjust period start in case of a class start
ATC  Lowest level of the Anatomical Therapeutic Chemical classification.132 Volume 33 Number 1
J. Voorham et al.Appendix II. Model results for continuous and categorical adherence assessments for distinct therapy
modifications.
Antihypertensive (n  4980) Glucose Regulating (n  2945)
OR* 95% CI OR* 95% CI
Intensification (binary)
MPR (10%) 1.04 0.99 1.10 0.92 0.87 0.98
Last gap (14 days) 1.00 0.97 1.04 0.93 0.87 0.98
MPR  80% 1.02 0.80 1.31 0.75 0.59 0.94
MPR  70% 1.17 0.89 1.55 0.77 0.58 1.02
Last gap  30 days 1.04 0.79 1.36 0.56 0.40 0.77
Last gap  15 days 1.07 0.86 1.33 0.59 0.46 0.76
Increase
MPR (10%) 1.02 0.93 1.12 0.92 0.85 0.98
Last gap (14 days) 1.00 0.93 1.08 0.88 0.81 0.96
MPR  80% 0.86 0.54 1.35 0.78 0.60 1.01
MPR  70% 1.02 0.61 1.71 0.76 0.54 1.06
Last gap  30 days 0.67 0.38 1.19 0.53 0.36 0.79
Last gap  15 days 0.93 0.63 1.38 0.63 0.47 0.84
Decrease
MPR (10%) 1.14 1.01 1.28 1.02 0.88 1.18
Last gap (14 days) 1.04 0.95 1.13 0.95 0.81 1.12
MPR  80% 1.78 1.03 3.08 1.33 0.77 2.29
MPR  70% 2.23 1.23 4.03 1.16 0.58 2.32
Last gap  30 days 1.40 0.74 2.64 1.07 0.50 2.28
Last gap  15 days 1.33 0.78 2.28 1.02 0.55 1.86
Switch
MPR (10%) 1.05 0.81 1.37 1.02 0.72 1.43
Last gap (14 days) 1.07 0.94 1.22 1.12 0.94 1.33
MPR  80% 1.15 0.32 4.20 1.23 0.33 4.62
MPR  70% 1.86 0.51 6.79 1.38 0.30 6.45
Last gap  30 days 1.64 0.45 5.92 2.75 0.72 10.45
Last gap  15 days 1.23 0.38 3.95 3.06 0.95 9.88
Addition
MPR (10%) 1.06 1.00 1.12 0.90 0.82 0.99
Last gap (14 days) 1.01 0.97 1.05 0.97 0.89 1.06
MPR  80% 1.15 0.87 1.52 0.68 0.46 1.01
MPR  70% 1.31 0.96 1.80 0.74 0.46 1.19
Last gap  30 days 1.20 0.89 1.62 0.62 0.37 1.05
Last gap  15 days 1.13 0.88 1.45 0.53 0.35 0.82January 2011 133
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Antihypertensive (n  4980) Glucose Regulating (n  2945)
OR* 95% CI OR* 95% CI
Discontinuation
MPR (10%) 1.22 1.11 1.33 0.99 0.85 1.15
Last gap (14 days) 1.11 1.05 1.17 1.06 0.94 1.20
MPR  80% 2.44 1.55 3.84 0.87 0.47 1.61
MPR  70% 2.37 1.42 3.94 1.01 0.48 2.11
Last gap  30 days 1.63 0.96 2.78 1.32 0.63 2.78
Last gap  15 days 1.22 0.76 1.97 1.03 0.55 1.94
Insulin start
MPR (10%) 1.00 0.79 1.27
Last gap (14 days) 1.06 0.89 1.26
MPR  80% 0.65 0.23 1.80
MPR  70% 0.73 0.21 2.53
Last gap  30 days 0.80 0.22 2.86
Last gap  15 days 0.59 0.19 1.78
MPR  medication possession ratio; OR  odds ratio.
* Boldface OR: P  0.05.134 Volume 33 Number 1
